ATE189856T1 - Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope - Google Patents

Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope

Info

Publication number
ATE189856T1
ATE189856T1 AT90909984T AT90909984T ATE189856T1 AT E189856 T1 ATE189856 T1 AT E189856T1 AT 90909984 T AT90909984 T AT 90909984T AT 90909984 T AT90909984 T AT 90909984T AT E189856 T1 ATE189856 T1 AT E189856T1
Authority
AT
Austria
Prior art keywords
membrane
secreted iga
bond
antigen epitopes
occurring
Prior art date
Application number
AT90909984T
Other languages
English (en)
Inventor
Tse Wen Chang
Nancy T Chang
Original Assignee
Tanox Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/369,479 external-priority patent/US5079344A/en
Application filed by Tanox Biosystems Inc filed Critical Tanox Biosystems Inc
Application granted granted Critical
Publication of ATE189856T1 publication Critical patent/ATE189856T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT90909984T 1989-06-21 1990-06-21 Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope ATE189856T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/369,479 US5079344A (en) 1989-06-21 1989-06-21 Antigenic epitopes present on membrane-bound but not secreted IgA
US07/455,080 US5089603A (en) 1989-06-21 1989-12-22 Antigenic epitopes present on membrane-bound but not secreted iga
PCT/US1990/003532 WO1990015614A1 (en) 1989-06-21 1990-06-21 ANTIGENIC EPITOPES PRESENT ON MEMBRANE-BOUND BUT NOT SECRETED IgA

Publications (1)

Publication Number Publication Date
ATE189856T1 true ATE189856T1 (de) 2000-03-15

Family

ID=27004597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90909984T ATE189856T1 (de) 1989-06-21 1990-06-21 Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope

Country Status (11)

Country Link
US (2) US5089603A (de)
EP (1) EP0478665B1 (de)
JP (1) JP2612512B2 (de)
AT (1) ATE189856T1 (de)
AU (1) AU645256B2 (de)
CA (1) CA2060666C (de)
DE (1) DE69033461T2 (de)
DK (1) DK0478665T3 (de)
ES (1) ES2142790T3 (de)
SG (1) SG52589A1 (de)
WO (1) WO1990015614A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362643A (en) * 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5514776A (en) * 1987-12-31 1996-05-07 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface
US5266477A (en) * 1990-02-02 1993-11-30 Pitman-Moore, Inc. Monoclonal antibodies which differentiate between native and modified porcine somatotropins
US20100267023A1 (en) * 1992-09-24 2010-10-21 Keygene N.V. Selective restriction fragment amplification: fingerprinting
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
IT1315254B1 (it) * 1999-11-05 2003-02-03 Diesse Diagnostica Senese Spa Metodo per la determinazione qualitativa e quantitativa di anticorpiumani di classe igc.
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP4696079B2 (ja) 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
KR101157694B1 (ko) * 2003-12-17 2012-06-20 와이어쓰 엘엘씨 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
EP1838348B1 (de) * 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1941275B1 (de) * 2005-09-29 2013-07-24 Medimmune, Inc. Verfahren zur identifizierung membran-lg-spezifischer antikörper und verwendung davon zur ansteuerung immunglobulin produzierender vorläuferzellen
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2401300B1 (de) 2009-02-25 2018-01-10 Academia Sinica AN MENSCHLICHE mIgE-AUF-B-LYMPHOZYTEN BINDENDE ANTI-C[epsilon]MX-ANTIKÖRPER
WO2013158274A1 (en) 2012-04-20 2013-10-24 Academia Sinica ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS
JP6316966B2 (ja) * 2013-12-05 2018-04-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ ｍＩｇＡ−Ｂリンパ球の溶解及びＩｇＡ生産の減少が可能な抗ヒトｍＩｇＡ抗体
WO2019085902A1 (en) 2017-10-31 2019-05-09 Fountain Biopharma Inc. Treating ige-mediated allergic diseases
US12497464B1 (en) 2018-08-03 2025-12-16 Berkeley Therapeutics, Inc. Antibody, antibody fragments or peptide for treating cancer and methods of formation and administration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE230883C (de) *
US4636463A (en) * 1984-04-05 1987-01-13 Scripps Clinic And Research Foundation Antibodies to human interleukin-2 induced by synthetic polypeptides
AU618317B2 (en) * 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes

Also Published As

Publication number Publication date
EP0478665A1 (de) 1992-04-08
JPH04504424A (ja) 1992-08-06
AU645256B2 (en) 1994-01-13
WO1990015614A1 (en) 1990-12-27
ES2142790T3 (es) 2000-05-01
CA2060666A1 (en) 1990-12-22
CA2060666C (en) 2001-07-10
EP0478665A4 (en) 1993-02-17
DK0478665T3 (da) 2000-07-24
AU5854790A (en) 1991-01-08
SG52589A1 (en) 1998-09-28
JP2612512B2 (ja) 1997-05-21
DE69033461T2 (de) 2000-10-12
EP0478665B1 (de) 2000-02-23
US5866129A (en) 1999-02-02
US5089603A (en) 1992-02-18
DE69033461D1 (de) 2000-03-30

Similar Documents

Publication Publication Date Title
ATE189856T1 (de) Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope
DK0722340T3 (da) Immunologisk toleranceinducerende middel
ATE109795T1 (de) Htlv-iii umhüllende peptiden.
ATE127024T1 (de) Immunogene komplexe, insbesondere iscoms.
DE3574730D1 (de) Monoklonaler antikoerper gegen ein humanes tumor-karzinom-assoziiertes antigen.
ATE377027T1 (de) Tetravalente antikörperkonstrukte
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
NO980293D0 (no) Fremgangsmåte til fremstilling av et polypeptid
DE69128273D1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
ES551496A0 (es) Procedimiento de obtencion de un anticuerpo monoclonal reactivo con antigenos de esporozoitos de eimeria spp.
ES2114064T3 (es) Inmunoanalisis para la deteccion de colageno o fragmentos de colageno.
ES551495A0 (es) Procedimiento de obtencion de un anticuerpo monoclonal reactivo con antigenos de esporozoitos o merozoitos de eimeria spp.
ES8802406A1 (es) Un metodo para detectar el anticuerpo para el antigeno superficial de la hepatitis b de subtipona como divisional de la patente de invencion 545.205 del 15-7-85
NO873774D0 (no) Monoklonale eller polyklonale antistoffer.
DE3585370D1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
ATE207935T1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
DE69836024D1 (de) Pseudomonas exotoxin a-ähnliche chimerische immunogene zum auslösen einer sekretorischen iga-vermittelten immunantwort
ES2061973T3 (es) Anticuerpos monoclonales que reconocen la region n-terminal de polipeptido natriuretico auricular, su preparacion y uso.
FI934963A7 (fi) CTAA 81AV78, monoklonaalisen 81AV78-humaanivasta-aineen tunnistama ant igeeni
ATE28937T1 (de) Immunotest fuer kohlehydrat-antigen-determinant.
PT84976A (pt) Method of producing feline leukemia virus antigens containing recombinant polypeptides
FI924576A7 (fi) CTAA 28A32, MCA 28A32:n tunnistama antigeeni
DK329789D0 (da) Monoklonalt antistof
MX9203574A (es) Metodo biotecnologico para la produccion de peptidos antigenicos relacionados con el antigeno p asociado al melanoma, y para preparar vacunas que los contienen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee